In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Can-Fite BioPharma initiates pivotal Phase 3 study for psoriasis treatment using oral drug Piclidenoson, targeting moderate to severe cases. Can-Fite BioPharma Ltd. announced the initiation of a ...

Can-Fite BioPharma Ltd. The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite ...